Reported Saturday, Lilly Presents Phase 1 AJX-101 Data At EHA 2026 Showing First-In-Class Type II JAK2 Inhibitor Delivers 70% Spleen Volume Reduction And Symptom Improvement In Myelofibrosis

Benzinga Newsdesk www.benzinga.com Positive 94.4%

Neg 0% Neu 0% Pos 94.4%

Comments

No comments yet. Be the first!